Novel Agents for the Management of Endocrine Resistant Breast Cancer.
Novel Agents for the Management of Endocrine Resistant Breast Cancer.
复制标题
治疗内分泌耐药乳腺癌的新药。
DOI：
10.1007/s12609-018-0298-3
复制
发表时间：
2018
影响因子：
0.9
通讯作者：
Mayer,IngridA
中科院分区：
文献类型：
--
作者：
Reid-Lawrence,Sonya;Mayer,IngridA
大多数激素受体（HR）阳性，HER2阴性（HR+/HER2 -）乳腺癌妇女最终会发展为内分泌抵抗疾病，无论是原发性的还是获得性的。本文将讨论内分泌抵抗的潜在机制以及内分泌抵抗乳腺癌治疗的主要进展。雌激素受体1突变（ESR1）发生在大多数HR+/HER2 -转移性乳腺癌患者长期暴露于芳香酶抑制剂后。来自SoFEA试验的数据显示，与依西美坦相比，服用氟维司汀后患者的无进展生存期（PFS）有所改善。Fulvestrant是目前唯一可用的选择性雌激素受体降解剂（SERD），目前正在研究开发具有更高生物利用度和效力的口服新型SERD。尽管在过去的40年里，HR+/HER2−乳腺癌的治疗取得了重大进展，但仍有相当一部分患者在接受最佳内分泌治疗后出现了内分泌抵抗。在这篇综述中，我们的目的是提供概述不同类别的新型药物目前正在研究克服内分泌抵抗。
Purpose of ReviewMost women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer.Recent FindingsEstrogen receptor 1 mutations (ESR1) occur in the majority of patients with HR+/HER2− metastatic breast cancer after prolonged exposure to aromatase inhibitors. Data from the SoFEA trial showed that patients had improved progression-free survival (PFS) after taking fulvestrant compared with exemestane. Fulvestrant is currently the only selective estrogen receptor degrader (SERD) available and development of oral novel SERDs with higher bioavailability and potency are currently being investigated.SummaryDespite significant advances in the treatment of HR+/HER2− breast cancer over the past four decades, a significant proportion of patients do still develop endocrine resistance following optimal endocrine therapy. In this review, we aim to provide an overview of the different classes of novel agents currently being investigated to overcome endocrine resistance.